SEC Form 4 · accession 0001209191-19-002201
Eiger BioPharmaceuticals, Inc. · EIGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sriram Ryali
Officer — Chief Financial Officer
Period of report
Jan 3, 2019
Accepted (ET)
Jan 4, 2019 · 5:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001305253
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option ( Right to Buy)F1 | $10.46 | Jan 3, 2019 | A | 90,000 | A | — | Jan 2, 2029 | Common Stock | 90,000 | 90,000 | D |
Explanation of responses
- F1The option will vest as to 25% of the option shares on December 17, 2019 and vest as to the remaining shares in successive equal monthly installments for the subsequent 36 months subject to Reporting Person's continuous service status as of each such date.